Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 123

1.

Cross-talk between TGF-β and PDGFRα signaling pathways regulates the fate of stromal fibro-adipogenic progenitors.

Contreras O, Cruz-Soca M, Theret M, Soliman H, Tung LW, Groppa E, Rossi FM, Brandan E.

J Cell Sci. 2019 Oct 9;132(19). pii: jcs232157. doi: 10.1242/jcs.232157.

PMID:
31434718
2.

Denervation-induced skeletal muscle fibrosis is mediated by CTGF/CCN2 independently of TGF-β.

Rebolledo DL, González D, Faundez-Contreras J, Contreras O, Vio CP, Murphy-Ullrich JE, Lipson KE, Brandan E.

Matrix Biol. 2019 Sep;82:20-37. doi: 10.1016/j.matbio.2019.01.002. Epub 2019 Feb 1.

PMID:
30716392
3.

CTGF/CCN2 from Skeletal Muscle to Nervous System: Impact on Neurodegenerative Diseases.

Gonzalez D, Brandan E.

Mol Neurobiol. 2019 Aug;56(8):5911-5916. doi: 10.1007/s12035-019-1490-9. Epub 2019 Jan 28. Review.

PMID:
30689195
4.

The inhibition of CTGF/CCN2 activity improves muscle and locomotor function in a murine ALS model.

Gonzalez D, Rebolledo DL, Correa LM, Court FA, Cerpa W, Lipson KE, van Zundert B, Brandan E.

Hum Mol Genet. 2018 Aug 15;27(16):2913-2926. doi: 10.1093/hmg/ddy204.

PMID:
29860398
5.

Nilotinib impairs skeletal myogenesis by increasing myoblast proliferation.

Contreras O, Villarreal M, Brandan E.

Skelet Muscle. 2018 Feb 20;8(1):5. doi: 10.1186/s13395-018-0150-5.

6.

Expression of CTGF/CCN2 in response to LPA is stimulated by fibrotic extracellular matrix via the integrin/FAK axis.

Riquelme-Guzmán C, Contreras O, Brandan E.

Am J Physiol Cell Physiol. 2018 Apr 1;314(4):C415-C427. doi: 10.1152/ajpcell.00013.2017. Epub 2017 Dec 27.

7.

Blockade of Bradykinin receptors worsens the dystrophic phenotype of mdx mice: differential effects for B1 and B2 receptors.

Acuña MJ, Salas D, Córdova-Casanova A, Cruz-Soca M, Céspedes C, Vio CP, Brandan E.

J Cell Commun Signal. 2018 Sep;12(3):589-601. doi: 10.1007/s12079-017-0439-x. Epub 2017 Dec 17.

8.

The pro-fibrotic connective tissue growth factor (CTGF/CCN2) correlates with the number of necrotic-regenerative foci in dystrophic muscle.

Morales MG, Acuña MJ, Cabrera D, Goldschmeding R, Brandan E.

J Cell Commun Signal. 2018 Mar;12(1):413-421. doi: 10.1007/s12079-017-0409-3. Epub 2017 Sep 8.

9.

Andrographolide Ameliorates Inflammation and Fibrogenesis and Attenuates Inflammasome Activation in Experimental Non-Alcoholic Steatohepatitis.

Cabrera D, Wree A, Povero D, Solís N, Hernandez A, Pizarro M, Moshage H, Torres J, Feldstein AE, Cabello-Verrugio C, Brandan E, Barrera F, Arab JP, Arrese M.

Sci Rep. 2017 Jun 14;7(1):3491. doi: 10.1038/s41598-017-03675-z.

10.

ALS skeletal muscle shows enhanced TGF-β signaling, fibrosis and induction of fibro/adipogenic progenitor markers.

Gonzalez D, Contreras O, Rebolledo DL, Espinoza JP, van Zundert B, Brandan E.

PLoS One. 2017 May 16;12(5):e0177649. doi: 10.1371/journal.pone.0177649. eCollection 2017.

11.

Fibro/adipogenic progenitors safeguard themselves: a novel mechanism to reduce fibrosis is discovered.

Contreras O, Brandan E.

J Cell Commun Signal. 2017 Mar;11(1):77-78. doi: 10.1007/s12079-016-0372-4. Epub 2016 Dec 20.

12.

Diet-Induced Nonalcoholic Fatty Liver Disease Is Associated with Sarcopenia and Decreased Serum Insulin-Like Growth Factor-1.

Cabrera D, Ruiz A, Cabello-Verrugio C, Brandan E, Estrada L, Pizarro M, Solis N, Torres J, Barrera F, Arrese M.

Dig Dis Sci. 2016 Nov;61(11):3190-3198. Epub 2016 Aug 29.

PMID:
27572941
13.

Analysis of Pathological Activities of CCN2/CTGF in Muscle Dystrophy.

Acuña MJ, Brandan E.

Methods Mol Biol. 2017;1489:513-521.

PMID:
27734402
14.

Angiotensin-(1-7) attenuates disuse skeletal muscle atrophy in mice via its receptor, Mas.

Morales MG, Abrigo J, Acuña MJ, Santos RA, Bader M, Brandan E, Simon F, Olguin H, Cabrera D, Cabello-Verrugio C.

Dis Model Mech. 2016 Apr;9(4):441-9. doi: 10.1242/dmm.023390. Epub 2016 Feb 5.

15.

Connective tissue cells expressing fibro/adipogenic progenitor markers increase under chronic damage: relevance in fibroblast-myofibroblast differentiation and skeletal muscle fibrosis.

Contreras O, Rebolledo DL, Oyarzún JE, Olguín HC, Brandan E.

Cell Tissue Res. 2016 Jun;364(3):647-660. doi: 10.1007/s00441-015-2343-0. Epub 2016 Jan 7.

PMID:
26742767
16.

Wnt signaling pathway improves central inhibitory synaptic transmission in a mouse model of Duchenne muscular dystrophy.

Fuenzalida M, Espinoza C, Pérez MÁ, Tapia-Rojas C, Cuitino L, Brandan E, Inestrosa NC.

Neurobiol Dis. 2016 Feb;86:109-20. doi: 10.1016/j.nbd.2015.11.018. Epub 2015 Dec 2.

PMID:
26626079
17.

RECK-Mediated β1-Integrin Regulation by TGF-β1 Is Critical for Wound Contraction in Mice.

Gutiérrez J, Droppelmann CA, Contreras O, Takahashi C, Brandan E.

PLoS One. 2015 Aug 6;10(8):e0135005. doi: 10.1371/journal.pone.0135005. eCollection 2015.

18.

Erratum for: Transforming growth factor type-β inhibits Mas receptor expression in fibroblasts but not in myoblasts or differentiated myotubes; Relevance to fibrosis associated to muscular dystrophies.

Cofre C, José Acuña M, Contreras O, Gabriela Morales M, Riquelme C, Bader M, Santos R, Cabello-Verrugio C, Brandan E.

Biofactors. 2015 May 6;41(3):209. doi: 10.1002/biof.1220. Epub 2015 Jun 12. No abstract available.

PMID:
26094753
19.

Endotoxin-induced skeletal muscle wasting is prevented by angiotensin-(1-7) through a p38 MAPK-dependent mechanism.

Morales MG, Olguín H, Di Capua G, Brandan E, Simon F, Cabello-Verrugio C.

Clin Sci (Lond). 2015 Sep;129(6):461-76. doi: 10.1042/CS20140840. Epub 2015 May 19.

PMID:
25989282
20.

Angiotensins as therapeutic targets beyond heart disease.

Passos-Silva DG, Brandan E, Santos RA.

Trends Pharmacol Sci. 2015 May;36(5):310-20. doi: 10.1016/j.tips.2015.03.001. Epub 2015 Apr 3. Review.

PMID:
25847571
21.

Transforming growth factor type-β inhibits Mas receptor expression in fibroblasts but not in myoblasts or differentiated myotubes; Relevance to fibrosis associated to muscular dystrophies.

Cofre C, Acuña MJ, Contreras O, Morales MG, Riquelme C, Cabello-Verrugio C, Brandan E.

Biofactors. 2015 Mar-Apr;41(2):111-20. doi: 10.1002/biof.1208. Epub 2015 Mar 23. Erratum in: Biofactors. 2015 May 6;41(3):209.

PMID:
25809912
22.

SMAD3 and SP1/SP3 Transcription Factors Collaborate to Regulate Connective Tissue Growth Factor Gene Expression in Myoblasts in Response to Transforming Growth Factor β.

Córdova G, Rochard A, Riquelme-Guzmán C, Cofré C, Scherman D, Bigey P, Brandan E.

J Cell Biochem. 2015 Sep;116(9):1880-7. doi: 10.1002/jcb.25143.

PMID:
25727481
23.

Heparan sulfate provides a mechanism to respond to FGFR2b and control regenerative expansion.

Brandan E.

J Cell Commun Signal. 2015 Mar;9(1):89. doi: 10.1007/s12079-015-0277-7. Epub 2015 Feb 26.

24.

The angiotensin-(1-7)/Mas axis reduces myonuclear apoptosis during recovery from angiotensin II-induced skeletal muscle atrophy in mice.

Meneses C, Morales MG, Abrigo J, Simon F, Brandan E, Cabello-Verrugio C.

Pflugers Arch. 2015 Sep;467(9):1975-84. doi: 10.1007/s00424-014-1617-9. Epub 2014 Oct 9.

PMID:
25292283
25.

Angiotensin-(1-7) decreases skeletal muscle atrophy induced by angiotensin II through a Mas receptor-dependent mechanism.

Cisternas F, Morales MG, Meneses C, Simon F, Brandan E, Abrigo J, Vazquez Y, Cabello-Verrugio C.

Clin Sci (Lond). 2015 Mar;128(5):307-19. doi: 10.1042/CS20140215.

PMID:
25222828
26.

Novel and optimized strategies for inducing fibrosis in vivo: focus on Duchenne Muscular Dystrophy.

Pessina P, Cabrera D, Morales MG, Riquelme CA, Gutiérrez J, Serrano AL, Brandan E, Muñoz-Cánoves P.

Skelet Muscle. 2014 Aug 25;4:7. doi: 10.1186/2044-5040-4-7. eCollection 2014.

27.

ACE2 is augmented in dystrophic skeletal muscle and plays a role in decreasing associated fibrosis.

Riquelme C, Acuña MJ, Torrejón J, Rebolledo D, Cabrera D, Santos RA, Brandan E.

PLoS One. 2014 Apr 2;9(4):e93449. doi: 10.1371/journal.pone.0093449. eCollection 2014.

28.

Andrographolide attenuates skeletal muscle dystrophy in mdx mice and increases efficiency of cell therapy by reducing fibrosis.

Cabrera D, Gutiérrez J, Cabello-Verrugio C, Morales MG, Mezzano S, Fadic R, Casar JC, Hancke JL, Brandan E.

Skelet Muscle. 2014 Mar 21;4:6. doi: 10.1186/2044-5040-4-6. eCollection 2014.

29.
30.

Restoration of muscle strength in dystrophic muscle by angiotensin-1-7 through inhibition of TGF-β signalling.

Acuña MJ, Pessina P, Olguin H, Cabrera D, Vio CP, Bader M, Muñoz-Canoves P, Santos RA, Cabello-Verrugio C, Brandan E.

Hum Mol Genet. 2014 Mar 1;23(5):1237-49. doi: 10.1093/hmg/ddt514. Epub 2013 Oct 24.

PMID:
24163134
31.

Wnt signaling in skeletal muscle dynamics: myogenesis, neuromuscular synapse and fibrosis.

Cisternas P, Henriquez JP, Brandan E, Inestrosa NC.

Mol Neurobiol. 2014 Feb;49(1):574-89. doi: 10.1007/s12035-013-8540-5. Epub 2013 Sep 7. Review.

PMID:
24014138
32.

Reducing CTGF/CCN2 slows down mdx muscle dystrophy and improves cell therapy.

Morales MG, Gutierrez J, Cabello-Verrugio C, Cabrera D, Lipson KE, Goldschmeding R, Brandan E.

Hum Mol Genet. 2013 Dec 15;22(24):4938-51. doi: 10.1093/hmg/ddt352. Epub 2013 Jul 30.

PMID:
23904456
33.

Inhibition of the angiotensin-converting enzyme decreases skeletal muscle fibrosis in dystrophic mice by a diminution in the expression and activity of connective tissue growth factor (CTGF/CCN-2).

Morales MG, Cabrera D, Céspedes C, Vio CP, Vazquez Y, Brandan E, Cabello-Verrugio C.

Cell Tissue Res. 2013 Jul;353(1):173-87. doi: 10.1007/s00441-013-1642-6. Epub 2013 May 15.

PMID:
23673415
34.

Mice long-term high-fat diet feeding recapitulates human cardiovascular alterations: an animal model to study the early phases of diabetic cardiomyopathy.

Calligaris SD, Lecanda M, Solis F, Ezquer M, Gutiérrez J, Brandan E, Leiva A, Sobrevia L, Conget P.

PLoS One. 2013 Apr 11;8(4):e60931. doi: 10.1371/journal.pone.0060931. Print 2013.

35.

Role of skeletal muscle proteoglycans during myogenesis.

Brandan E, Gutierrez J.

Matrix Biol. 2013 Aug 8;32(6):289-97. doi: 10.1016/j.matbio.2013.03.007. Epub 2013 Apr 11. Review.

36.

Role of proteoglycans in the regulation of the skeletal muscle fibrotic response.

Brandan E, Gutierrez J.

FEBS J. 2013 Sep;280(17):4109-17. doi: 10.1111/febs.12278. Epub 2013 May 2. Review.

37.

Transforming growth factor type beta 1 increases the expression of angiotensin II receptor type 2 by a SMAD- and p38 MAPK-dependent mechanism in skeletal muscle.

Painemal P, Acuña MJ, Riquelme C, Brandan E, Cabello-Verrugio C.

Biofactors. 2013 Jul-Aug;39(4):467-75. doi: 10.1002/biof.1087. Epub 2013 Mar 5.

PMID:
23460581
38.

Angiotensin II-induced pro-fibrotic effects require p38MAPK activity and transforming growth factor beta 1 expression in skeletal muscle cells.

Morales MG, Vazquez Y, Acuña MJ, Rivera JC, Simon F, Salas JD, Alvarez Ruf J, Brandan E, Cabello-Verrugio C.

Int J Biochem Cell Biol. 2012 Nov;44(11):1993-2002. doi: 10.1016/j.biocel.2012.07.028. Epub 2012 Aug 7.

PMID:
22964022
39.
40.

CTGF/CCN-2 over-expression can directly induce features of skeletal muscle dystrophy.

Morales MG, Cabello-Verrugio C, Santander C, Cabrera D, Goldschmeding R, Brandan E.

J Pathol. 2011 Dec;225(4):490-501. doi: 10.1002/path.2952. Epub 2011 Aug 8.

PMID:
21826667
41.

Fibrotic response induced by angiotensin-II requires NAD(P)H oxidase-induced reactive oxygen species (ROS) in skeletal muscle cells.

Cabello-Verrugio C, Acuña MJ, Morales MG, Becerra A, Simon F, Brandan E.

Biochem Biophys Res Commun. 2011 Jul 8;410(3):665-70. doi: 10.1016/j.bbrc.2011.06.051. Epub 2011 Jun 12.

PMID:
21693104
42.

Angiotensin II receptor type 1 blockade decreases CTGF/CCN2-mediated damage and fibrosis in normal and dystrophic skeletal muscles.

Cabello-Verrugio C, Morales MG, Cabrera D, Vio CP, Brandan E.

J Cell Mol Med. 2012 Apr;16(4):752-64. doi: 10.1111/j.1582-4934.2011.01354.x.

43.

Decorin interacts with connective tissue growth factor (CTGF)/CCN2 by LRR12 inhibiting its biological activity.

Vial C, Gutiérrez J, Santander C, Cabrera D, Brandan E.

J Biol Chem. 2011 Jul 8;286(27):24242-52. doi: 10.1074/jbc.M110.189365. Epub 2011 Mar 23.

44.

Connective tissue growth factor induction by lysophosphatidic acid requires transactivation of transforming growth factor type β receptors and the JNK pathway.

Cabello-Verrugio C, Córdova G, Vial C, Zúñiga LM, Brandan E.

Cell Signal. 2011 Feb;23(2):449-57. doi: 10.1016/j.cellsig.2010.10.019. Epub 2010 Oct 18.

PMID:
20965247
45.

Uptake of tritiated liquids by individual breakfast cereal flakes.

Medina WT, Laurent S, Brandan E, Aguilera JM.

J Food Sci. 2010 Apr;75(3):E194-200. doi: 10.1111/j.1750-3841.2010.01562.x.

PMID:
20492294
46.

TGF-beta receptors, in a Smad-independent manner, are required for terminal skeletal muscle differentiation.

Droguett R, Cabello-Verrugio C, Santander C, Brandan E.

Exp Cell Res. 2010 Sep 10;316(15):2487-503. doi: 10.1016/j.yexcr.2010.04.031. Epub 2010 May 13.

PMID:
20471380
47.

Syndecan-4 and beta1 integrin are regulated by electrical activity in skeletal muscle: Implications for cell adhesion.

Ugarte G, Santander C, Brandan E.

Matrix Biol. 2010 Jun;29(5):383-92. doi: 10.1016/j.matbio.2010.03.003. Epub 2010 Mar 31.

PMID:
20362053
48.

A novel mechanism of sequestering fibroblast growth factor 2 by glypican in lipid rafts, allowing skeletal muscle differentiation.

Gutiérrez J, Brandan E.

Mol Cell Biol. 2010 Apr;30(7):1634-49. doi: 10.1128/MCB.01164-09. Epub 2010 Jan 25.

49.
50.

Supplemental Content

Loading ...
Support Center